New immunisation reference page: Multi-dose vials
Our new reference page Multi-dose vials details the safe preparation and storage of vaccines from multi-dose vials that require reconstitution and from those that do not, as well as infection control and storage and handling principles to consider.
To access this resource please visit our Tài liệu tham khảo tiêm chủng or follow the link below:
Imperial College London survey suggests confidence in coronavirus vaccines is rising globally
A recent survey from the Imperial College London’s Institute of Global Health Innovation has shown that willingness to receive a COVID-19 vaccine is increasing.
The survey was initially run in November 2020 across 15 countries and demonstrated that just 41% of people would be willing to get vaccinated against COVID-19 at the time. This number has risen to 54% in results from the same survey, run again in January 2021. Results demonstrated vast differences in attitudes towards vaccination based on location, with 78% of people surveyed in the UK willing to be vaccinated with a COVID-19 vaccine. People in France demonstrated the least willingness, with 44% of people stating they would not be vaccinated.
The survey further demonstrated that worry over vaccine side effects has decreased in 9 of the 15 countries who participated. The report is part of a global effort to monitor health related behaviours and attitudes during the pandemic to inform decision-makers based on a country’s needs.
Read more about the results of the survey via the link below:
Imperial College London: Confidence in coronavirus vaccines is rising globally, survey suggests
ASCIA release COVID-19 vaccination position statement
The Australasian Society of Clinical Immunology and Allergy (ASCIA) have released a position statement on COVID-19 vaccination. The statement reflects the COVID-19 vaccines the Therapeutic Goods Administration (TGA) has granted provisional approval for use in Australia, as well as vaccines that may also be granted provisional approval in the future. It contains guidance based on current data for COVID-19 vaccination in people with allergic conditions, immunodeficiencies and autoimmune conditions, pregnant and breastfeeding women and children under 16 years of age.
You can access the full statement via the link below:
ASCIA: Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination Position Statement
Community pharmacies to participate in COVID-19 vaccination program
The Australian Government has announced an expression of interest (EOI) process has begun for community pharmacies to participate in the COVID-19 vaccination program.
Participation is voluntary, with pharmacies needing to demonstrate their capacity, capability and ability to meet high safety standards.
Eligible pharmacies would be able to deliver COVID-19 vaccines to priority populations from phase 2a of the of Australian COVID-19 vaccination rollout strategy (expected to be in May 2021). They would be incentivised to provide both doses of the AstraZeneca COVID-19 vaccine in an effort to increase uptake of the vaccine.
Read more about this in the Health Minister’s statement via the link below:
Community Pharmacy to join COVID-19 vaccine workforce
ATAGI tư vấn về vắc xin cúm và COVID-19
Các Nhóm tư vấn kỹ thuật về tiêm chủng Úc (ATAGI) đã công bố lời khuyên liên quan đến việc sử dụng vắc-xin cúm và COVID-19.
Do thiếu dữ liệu về tính an toàn và khả năng sinh miễn dịch khi sử dụng đồng thời các loại vắc xin này, do đó, khuyến cáo không nên tiêm vắc xin cúm và vắc xin COVID-19 trong cùng một ngày mà cách nhau tối thiểu 14 ngày. Không có ưu tiên nào về thứ tự tiêm vắc xin, lưu ý rằng cả vắc xin Oxford/AstraZeneca và Pfizer/BioNTech COVID-19 đều yêu cầu lịch tiêm 2 liều. Nếu vắc-xin cúm và vắc-xin COVID-19 vô tình được tiêm trong cùng một ngày hoặc được tiêm trong khoảng thời gian ngắn hơn 14 ngày, thì không nên tiêm lại một trong hai loại vắc-xin.
Để đọc lời khuyên đầy đủ, hãy tham khảo liên kết dưới đây:
ATAGI tư vấn về vắc xin cúm và COVID-19
Cuộc họp của tiểu ban An toàn vắc xin COVID-19 của GACVS để xem xét các báo cáo về trường hợp tử vong của những người cao tuổi rất yếu được tiêm vắc xin Pfizer BioNTech COVID-19, BNT162b2
Vai trò của Ủy ban Cố vấn Toàn cầu về An toàn Vắc xin (GACVS) là cung cấp lời khuyên chuyên môn, độc lập cho Tổ chức Y tế Thế giới về sự an toàn của vắc xin.
Vào ngày 19 tháng 1 năm 2021, một cuộc họp ảo đã được tổ chức để xem xét tất cả thông tin hiện có về các trường hợp tử vong được báo cáo ở những người già yếu đã tiêm vắc xin COVID-19 của Pfizer/BioNTech. Theo đánh giá này, người ta kết luận rằng việc tiêm phòng không góp phần gây ra bất kỳ sự gia tăng bất ngờ nào về số ca tử vong ở nhóm bệnh nhân này. Do đó, không có thay đổi nào trong các khuyến nghị về tính an toàn của vắc xin Pfizer/BioNTech COVID-19.
Để đọc thêm, hãy theo liên kết dưới đây:
Complete program for the CVU Miniseries virtual event now available
The next Clinical Vaccinology Update Miniseries event, COVID-19 vaccines: a Victorian landscape, will be held virtually on February 8th, 2021.
We are excited to welcome our presenters who will be covering the COVID-19 vaccine landscape in Victoria, including vaccine safety, Victorian COVID-19 vaccine rollout plans and stakeholder engagement and participation.
This is a free event, however you will need to register for tickets via the link below, where you can also view the complete program:
CVU Miniseries: February 8, 2021
New immunisation reference page: COVAX Facility
The COVAX Facility is coordinated by Gavi (the Vaccine Alliance), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization. It brings together governments of over 180 countries, global health organisations, private sector, scientists and manufacturers, in order to provide innovative and equitable access to COVID-19 diagnostics, treatments and vaccines. Our new reference page details information on the COVAX Facility COVID-19 vaccine portfolio.
To read more please refer to the link below:
New immunisation reference pages: COVID-19 vaccines
In 2020, the Australian Government entered into four Advance Purchase Agreements (APA) for the supply of COVID-19 vaccines, if they prove safe and effective. More than $3.3 billion has been invested through these agreements, putting Australia in a strong position to access safe and effective vaccines when they become available. In 2021, three of these vaccines are still active, with the 4quần què (University of Queensland) withdrawn from clinical trials. Our new reference pages detail information regarding the clinical trials of each vaccine candidate, interim data on their safety and efficacy, as well as other vaccine specific information.
To read more please refer to the links below:
- MVEC: University of Oxford/AstraZeneca COVID-19 vaccine
- MVEC: Pfizer/BioNTech COVID-19 vaccine
- MVEC: Novavax COVID-19 vaccine
CNN: How some states are administering Covid-19 vaccines at twice the speed of others
Data from the CDC reveals that of the 31 million doses of COVID-19 vaccine that have been distributed to the various jurisdictions in the United States, only 39% (12.2 million doses) have actually been administered. Those states with the highest vaccination rates have suggested that preparation, communication and strategic planning have been vital in vaccine rollout.
Để đọc thêm theo liên kết dưới đây:
CNN: How some states are administering Covid-19 vaccines at twice the speed of others